NCT03749421View on ClinicalTrials.gov

Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

November 29, 2023

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
OTHER

Prosigna PAM-50 assay

Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

NanoString Technologies, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03749421 - Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer | Biotech Hunter | Biotech Hunter